Carlyle snaked the business away from several other PE groups who submitted 1st-round bids in September 2013, including Blackstone Group, Kohlberg Kravis Roberts, Bain Capital and BC Partners.
The PE giant agreed to pay $4.15 billion for the J&J blood testing unit.
Madaus, the former chief executive at Roche (PINK:RHHBY) and Millipore before it was bought out in 2010 by Merck KGaA, stepped down from his board seat with Covidien (NYSE:COV) in early February in preparation for the gig with Ortho-Clinical Diagnostics. He is taking over for Eric Compton, who will stay on until the deal closes, according to a press release.
“As an experienced executive with an exemplary track record of growing businesses, Martin can lead OCD through its transition to an independent company and transformation into a leading diagnostics platform. We believe our long-term partnership with Martin in the in vitro diagnostics industry will create significant value for our investors over the coming years,” Carlyle managing director Stephen Wise said in prepared remarks.
Registration is open for DeviceTalks Boston! Join us on June 5-6, 2019, as we explore the trends and technology that are shaping the future of the medical device industry.